Jeremy Levin spotlights a trendy new way to build a pipeline with his $86M IPO for Ovid
Jeremy Levin is a trend-setter. A decade ago he helped fashion the whole legendary “String of Pearls” model for Bristol-Myers as strategy chief. He was probably a little ahead of his time — though perfectly in sync with the industry — in looking to restructure Teva as pharma was applying the ax liberally to bloated, unproductive organizations when he took over in 2012. And after he got bounced by the Teva board just 18 months later, he jumped into neurosciences and formed Ovid Therapeutics as a wave of upstarts looked to use new technologies and scientific insights to revive a struggling field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
